Theranos, Inc.
Blood testing startup whose founder fabricated testing capabilities, commercial partnership revenues, and military contract claims.
- Entity Name: Theranos, Inc.
- Country of Domicile: US
- Listing & Ticker: Private.
- CIK / LEI Identifier: Unregistered.
- Industry Classification: General Commercial.
- Cumulative Overstatement: $700.0M across 1 enforcement episode(s).
- Assessed Penalties: $500K.
PRIMARY ENFORCEMENT CASES INVOLVING THERANOS, INC.
1 CASE DOSSIERS| Case Title | Status | Primary Scheme | Overstatement | Total Penalties | Action Date |
|---|---|---|---|---|---|
| Theranos: Fabricated Revenue Projections and Fake Blood Analyzer Demos | Adjudicated | misleading non gaap and kpis | $700.0M | $500K | September 20, 2020 |
FORENSIC PROFILE: THERANOS: FABRICATED REVENUE PROJECTIONS AND FAKE BLOOD ANALYZER DEMOS
FULL CASE DOSSIER →Elizabeth Holmes and Sunny Balwani deceived investors with fake DOD contract claims, false revenues, and proprietary analyzer demos run on commercial machines.
The company manipulated its accounting records by executing schemes under misleading-non-gaap-and-kpis. Financial reports filed with market regulators contained material misstatements that distorted true financial condition.
Fraud Window: January 1, 2018 to December 31, 2020 • Primary Regulator: U.S. Securities and Exchange Commission • Auditor: PricewaterhouseCoopers LLP
Documented Accounting Irregularities & Regulatory Findings
- MISLEADING NON GAAP AND KPIS: Elizabeth Holmes and Sunny Balwani deceived investors with fake DOD contract claims, false revenues, and proprietary analyzer demos run on commercial machines.
Primary Public Dockets & Actions
- [ENF-2018-theranos] Enforcement Action: Theranos: Fabricated Revenue Projections and Fake Blood Analyzer Demos (September 20, 2020): Elizabeth Holmes and Sunny Balwani deceived investors with fake DOD contract claims, false revenues, and proprietary analyzer demos run on commercial machines. Official Record ↗